Journal article
Differential Outcomes and Biologic Markers of Radiation-Associated vs. Sporadic Osteosarcoma: A Single-Institution Experience
Frontiers in oncology, Vol.9, pp.1523-1523
01/22/2020
DOI: 10.3389/fonc.2019.01523
PMCID: PMC6987384
PMID: 32039013
Abstract
Background: Radiation-associated osteosarcoma (RAO) is a rare, life-threatening complication from radiation. Many physicians presume RAO has a worse prognosis than sporadic osteosarcoma (SO), although limited objective data exist. We conducted a retrospective study comparing these entities.
Methods: We identified adults treated at our institution with osteosarcoma (1990-2016) and categorized tumors as SO or RAO based on location within a prior radiation field. We extracted data on demographics, treatment and primary malignancy and examined available tumor samples for MTA-1 and ezrin using immunohistochemistry (IHC).
Results: Of 159 identified patients, 28 had RAO, diagnosed at a median interval from radiation of 11.5 years (1.5-28 years). Median follow-up was 2.8 years (0.1-19.6 years). Median progression free survival (PFS) and overall survival (OS) were not significantly different in the small population of patients with metastases, SO (n = 20) vs. RAO (n = 6): PFS 10.3 months vs. 4.8 months (p = 0.45) and OS 15.6 months vs. 6.1 months (p = 0.96), respectively. For the larger group with localized disease, median relapse-free survival (RFS) and OS were significantly different, NR vs. 12.2 months (p < 0.001) and NR vs. 27.6 months (p = 0.001) in SO (n = 111) vs. RAO (n = 22), respectively. On IHC, there were significant differences in distribution of high, intermediate or low MTA-1 (p = 0.015) and ezrin (p = 0.002) between RAO and SO tumors.
Conclusions: Patients with metastases at diagnosis fared poorly irrespective of prior radiation. RAO patients with localized disease had worse outcomes without detectable differences in therapy rendered or treatment effect in resected specimens. Higher expression of MTA-1 in RAO patients may suggest an underlying difference in tumor biology to explain differences in outcomes.
Details
- Title: Subtitle
- Differential Outcomes and Biologic Markers of Radiation-Associated vs. Sporadic Osteosarcoma: A Single-Institution Experience
- Creators
- Brittany L. Siontis - University of MichiganJonathan B. McHugh - University of MichiganEmily Roberts - University of MichiganLily Zhao - University of MichiganDafydd G. Thomas - University of MichiganDawn Owen - University of MichiganLaurence H. Baker - University of MichiganJ. Sybil Biermann - University of MichiganScott M. Schuetze - University of MichiganRashmi Chugh - University of Michigan
- Resource Type
- Journal article
- Publication Details
- Frontiers in oncology, Vol.9, pp.1523-1523
- DOI
- 10.3389/fonc.2019.01523
- PMID
- 32039013
- PMCID
- PMC6987384
- NLM abbreviation
- Front Oncol
- ISSN
- 2234-943X
- eISSN
- 2234-943X
- Publisher
- Frontiers Media Sa
- Number of pages
- 7
- Grant note
- P30CA046592 / National Cancer Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 01/22/2020
- Academic Unit
- Biostatistics
- Record Identifier
- 9984274664002771
Metrics
9 Record Views